B

    Bone Biologics Corp (BBLG)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.58
    -0.04 (-6.18%)

    Market Cap: $1.70M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(14/20)
    Avg Surprise
    -2.32%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.19
    Range$-0.19 - $-0.19
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.36-89.5%
    60d ago$-0.36-89.5%
    30d ago$-0.18+5.3%
    7d ago$-0.18+5.3%
    Current$-0.19
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.11
    Range$-0.11 - $-0.11
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.11---
    Sep 26EST
    		-$-0.19---
    Jun 26
    		$-0.43$-0.39-10.26%Miss+67.7%
    Mar 26
    		$-0.43$-0.54+20.37%Beat-34.6%
    Dec 25
    		$-0.63$-0.34-85.29%Miss+78.1%
    Sep 25
    		$-0.37N/A+69.92%Beat+97.4%
    Jun 25
    		$-1.33$-0.58-129.31%Miss+66.9%
    Mar 25
    		$-0.32N/A+95.84%Beat+95.9%
    Dec 24
    		$-2.88$-3.90+26.15%Beat-16.6%
    Sep 24
    		$-14.22$-3.60-295.00%Miss+51.4%
    Jun 24
    		$-4.02N/A+51.80%Beat+95.0%
    Mar 24
    		$-7.86N/A+82.76%Beat+97.6%
    Dec 23
    		$-2.47N/A+55.89%Beat-1272.2%
    Sep 23
    		$-29.28N/A+79.93%Beat+83.1%
    Jun 23
    		$-81.12$-72.00-12.67%Miss-12.7%
    Mar 23
    		$-331.20$-100.80-228.57%Miss-228.6%
    Dec 22
    		$-0.18$-0.22+18.18%Beat-260.0%
    Sep 22
    		$-172.80$-216.00+20.00%Beat-101547.1%
    Jun 22
    		$-72.00N/A+58.33%Beat-102757.1%
    Mar 22
    		$-100.80N/A+65.00%Beat-167900.0%
    Dec 21
    		$-0.05N/A+70.59%Beat+99.9%
    Sep 21
    		$-0.17$-0.17+0.00%Beat+99.9%
    Jun 21
    		$-0.07N/AN/ABeat+100.0%
    Mar 21
    		$-0.06N/AN/ABeat+100.0%
    Dec 20
    		$-53.23N/AN/ABeat-75948.7%
    Sep 20
    		$-194.90N/AN/ABeat-243530.0%
    Jun 20
    		$-187.97N/AN/ABeat-144492.2%
    Mar 20
    		$-295.24N/AN/ABeat-155288.4%
    Dec 19
    		$-0.07N/AN/ABeat+81.6%
    Sep 19
    		$-0.08N/AN/ABeat-166.7%
    Jun 19
    		$-0.13N/AN/ABeat+55.2%
    Mar 19
    		$-0.19N/AN/ABeat-216.7%
    Dec 18
    		$-0.38N/AN/ABeat+100.0%
    Sep 18
    		$-0.03N/AN/ABeat+50.0%
    Jun 18
    		$-0.29N/AN/ABeat-1550.0%
    Mar 18
    		$-0.06N/AN/ABeat+25.0%
    Dec 17
    		$-2160.00N/AN/ABeat+52.2%
    Sep 17
    		$-0.06N/AN/ABeat+100.0%
    Jun 17
    		$0.02N/AN/ABeat-
    Mar 17
    		$-0.08N/AN/ABeat-
    Dec 16
    		$-4523.44N/AN/ABeat-
    Sep 16
    		$-4053.76N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.31EV/EBITDA0.14x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-55.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.67xQuick Ratio8.67x
    Trading Statistics
    Beta0.53Avg Volume829.36K
    52-Week High$4.1352-Week Low$0.58

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.61
    SMA 20$0.72
    SMA 50$1.02
    SMA 200$1.32
    EMA 10$0.63
    EMA 20$0.72
    EMA 50$0.92
    EMA 200$1.49

    MACD

    Line: -0.12Signal: -0.13Hist: 0.01

    ADX

    ADX: 38.0+DI: 10.2-DI: 29.5

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$0.70

    Bollinger Bands

    Upper Band$1.01
    Lower Band$0.43
    %B Position7995%(Upper)
    Band Width0.25

    RSI (14-Day)

    Oversold
    23.9

    Momentum Oscillators

    Stoch %K9.8
    Stoch %D8.7
    Williams %R-88.3
    ROC (10d)-12.6%
    Momentum-0.08
    CCI (20d)-70.1
    MFI (14d)1.2

    Volatility Measures

    ATR (14d)$0.07(11.3%)
    StdDev (20d)0.14
    Hist Vol110.7%(High)

    Volume Flow

    VWAP$0.58
    OBV150.9M
    AD Line563.9M
    CMF (20d)-0.202

    Volume Metrics

    Avg Vol (20d)866.3K
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.66

    Pivot Points

    R3$0.66
    R2$0.64
    R1$0.63
    Pivot Point$0.60
    S1$0.59
    S2$0.57
    S3$0.56

    Advanced Oscillators

    TSI-49.31
    Ultimate Osc62.7
    KST-403.61

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$0
    Gross ProfitN/AN/AN/AN/AN/AN/AN/A$0N/AN/AN/A$0
    Operating Expenses$808,106$805,054$733,107$715,274$748,075$1.04M$1.55M$951,021$809,665$903,536$1.16M$2.08M
    R&D$308,747$141,597$257,199$187,808$191,608$423,576$1.10M$429,747$350,442$245,625$447,077$1.57M
    SG&A$499,359$663,457$475,908$527,466$556,467$614,910$450,368$521,274$459,223$657,911$712,931$506,040
    Operating Income$-808,106$-805,054$-733,107$-715,274$-748,075$-1,038,486$-1,554,938$-951,021$-809,665$-903,536$-1,160,000$-2,081,000
    Interest Income$0$38,801$47,964$47,325$6,654$20,039$20,264$19,993$15,147$255$349$536
    Interest Expense$0$0$0$0$0$0$0$0$0$0$562,362$0
    Income Before Tax$-773,702$-765,988$-684,643$-666,737$-740,519$-1,017,092$-1,521,715$-941,002$-783,733$-865,970$-1,550,000$-1,920,000
    Income Tax Expense$0$0$0$0$0$0$903,536$0$-809,665$-904,000$-349$-2,080
    Net Income$-773,702$-765,988$-684,643$-666,737$-740,519$-1,017,092$-1,521,715$-941,002$-783,733$-865,970$-1,550,000$-1,920,000
    EBITDA$-773,702$-765,988$-677,087$48,537$-740,519$-1,017,092$-1,521,715$-941,002$-783,733$-865,970$-844,797$161,000
    EBITN/AN/A$-677,087$-666,737$-748,075$-1,038,000$-1,554,000$-891,021$-810,000$-796,536$-1,550,000$-1,920,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BBLG

    News

    Bone Biologics (NASDAQ: BBLG) seeks 1-for-2 to 1-for-10 reverse split approval

    Bone Biologics (NASDAQ: BBLG) is seeking stockholder approval for a reverse stock split in a range of 1-for-2 to 1-for-10, aiming to maintain its Nasdaq listing and increase its per-share price. The company is also seeking approval to issue up to 4,352,115 common shares related to warrants from a recent private placement, which generated $2.7 million in net proceeds and could yield an additional $6.0 million if warrants are fully exercised. Stockholders will vote on these and other governance items at the rescheduled annual meeting on September 28, 2026.

    Stock Titan•8/18/26•
    Somewhat-Bearish

    Price to sales forward of Bone Biologics Corp – NASDAQ:BBLGW

    This article provides the "Price to sales forward" metric for Bone Biologics Corp (NASDAQ: BBLGW). It indicates that the market was closed at the time of viewing and no trades were recorded for the stock. The content is primarily a data point from TradingView's financial section for the company.

    TradingView•8/18/26•
    Neutral

    Bone Biologics Raises $2.7M, Extends Cash Runway to Q2 2027

    Bone Biologics (Nasdaq: BBLG) reported a net loss of $1.54 million for H1 2026, an improvement from the previous year. The company secured approximately $2.7 million in net proceeds from a private placement in July 2026, which is expected to extend its cash runway into Q2 2027. Despite this, the company still anticipates needing additional financing to fully fund its development plans, highlighting ongoing financial risks for investors.

    Minichart•8/15/26•
    Somewhat-Bearish

    Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1

    Bone Biologics Corporation has announced a validated shelf life extension for its rhNELL-1 protein to 32 months. This milestone is crucial for manufacturing flexibility, inventory management, and distribution planning as the company prepares for a pivotal study. The extension supports the ongoing development of NB1, their lead product candidate for bone regeneration in spinal fusion procedures.

    Yahoo Finance•8/12/26•
    Bullish

    Bone Biologics Validates 32-Month Storage Life for Bone Protein

    Bone Biologics (NASDAQ: BBLG) announced the extension of its rhNELL-1 protein's validated shelf life to 32 months, supported by third-party stability data. This milestone aims to enhance manufacturing flexibility, inventory management, and distribution as the company prepares for pivotal studies for its lead product candidate, NB1, which is currently undergoing a pilot study in Australia for degenerative disc disease. Following the announcement, BBLG stock saw a 7.57% increase, reflecting a positive market reaction.

    Stock Titan•8/12/26•
    Bullish

    Frequently Asked Questions About BBLG

    Does BBLG pay dividends?
    Bone Biologics Corp (BBLG) does not currently pay a regular dividend.
    What is BBLG's market cap?
    Bone Biologics Corp (BBLG) has a market capitalization of $1.70M with a current stock price of $0.58.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In